Preeclampsia
Conditions
Brief summary
Investigation of cardiovascular risk 5-15 years after early or late-onset preeclampsia by adenosine stress Magnetic Resonance Imaging and non-invasive methods like retinal vessel analysis, skin measurement of advanced glycation end products, flow-mediated dilation or pulse wave analysis in comparison to women after healthy pregnancies.
Interventions
None listed
Sponsors
Charite University, Berlin, Germany
Study design
Observational model
CASE_CONTROL
Time perspective
OTHER
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Women * 18-60 years * 5-15 years postpartum
Exclusion criteria
* Atrioventricular block, chronic obstructive pulmonary disease, bronchial asthma * Pregnancy and/or active breastfeeding * Glaucoma disease, epilepsy * In addition for MRI: metal implants, electric devices, intolerance of contrast media, claustrophobia, renal or hepatic dysfunction (GFR \< 30 ml/min)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Myocardial perfusion | Day 2 | Measured by adenosine stress Magnetic Resonance Imaging (ml/min/g) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Immune cell phenotypes | Day 1 | Measured in isolated peripheral blood mononuclear cells |
| Concentration of N-terminal prohormone of brain natriuretic peptide | Day 1 | Measured in serum (ng/l) |
| Concentration of brain natriuretic peptide | Day 1 | Measured in serum (ng/l) |
| Urinary protein | Day 1 | Measured in spot urine (mg) |
| Advanced glycation end products | Day 1 | Measured by skin autofluorescence (arbitrary units) |
| Body fat mass | Day 1 | Measured by bioimpedance analysis (%) |
| Body fat-free mass | Day 1 | Measured by bioimpedance analysis (%) |
| Hand grip strength | Day 1 | Measured by dynamometer (kg) |
| Cardiac fibrosis | Day 2 | Measured by Magnetic Resonance Imaging (g) |
| Diastolic blood pressure | Day 1 | Mean of three consecutive blood pressure measurements (mmHg) |
| Pulse wave velocity | Day 1 | Calculated by algorithm based on age and blood pressure values (m/s) |
| Flow-mediated dilation | Day 1 | Measured by brachial artery diameter (µm) |
| Reactive hyperemia index | Day 1 | Measured by finger plethysmography |
| Choroidal thickness | Day 1 | Measured with Optical Coherence Tomography (µm) |
| Macular volume | Day 1 | Measured with Optical Coherence Tomography (mm³) |
| Arterial dilation induced by retinal flicker stimulation | Day 1 | Measured with Dynamic Vessel Analyser (seconds) |
| Venous dilation induced by retinal flicker stimulation | Day 1 | Measured with Dynamic Vessel Analyser (seconds) |
| Systolic blood pressure | Day 1 | Mean of three consecutive blood pressure measurements (mmHg) |
Countries
Germany
Contacts
Primary ContactKristin Kräker, PhD
Outcome results
None listed